These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25802925)

  • 21. [Editorial: adverse drug reactions].
    Taegtmeyer AB
    Ther Umsch; 2015 Dec; 72(11-12):667. PubMed ID: 26654808
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.
    Al Hail M; Elkassem W; Hamad A; Abdulrouf P; Thomas B; Stewart D
    Int J Clin Pharm; 2018 Aug; 40(4):769-774. PubMed ID: 29616393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Communicating vaccine safety - the Vienna Vaccine Safety Initiative.
    Rath B
    Curr Drug Saf; 2015; 10(1):3-4. PubMed ID: 25859667
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective.
    Swamy S; Mourya M; Kadhe G; Mane A; Sawant S
    Expert Opin Drug Saf; 2015; 14(9):1409-20. PubMed ID: 26292785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
    Prescrire Int; 2015 Apr; 24(159):107-10. PubMed ID: 25941710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
    EUROmediCAT Steering Group
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():3-7. PubMed ID: 26395593
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation Rules as a First Step for Data Quality: Pharmacovigilance Application in Portugal.
    Costa B; Figueiredo B; Pinheiro V
    Stud Health Technol Inform; 2023 May; 302():382-383. PubMed ID: 37203696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events.
    Chandler RE
    BMJ; 2019 May; 365():l2268. PubMed ID: 31151960
    [No Abstract]   [Full Text] [Related]  

  • 40. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions.
    Sessa M; Rossi C; Rafaniello C; Mascolo A; Cimmaruta D; Scavone C; Fiorentino S; Grassi E; Reginelli A; Rotondo A; Sportiello L
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):51-59. PubMed ID: 27855534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.